RVT 3101 (previously known as PF 6480605) is a fully human immunoglobulin G1 monoclonal antibody, targeting TL1A, being developed by Roche, for the treatment of
Roche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1 Under the terms of the agreement, Roche will pay a purchase price of $7.1 billion upfront and a near-term m...